TD Cowen 46th Annual Health Care Conference March 2, 2026 11:50 AM ESTCompany ParticipantsLarry Wood - President, ...

Truist lowered the firm’s price target on Procept BioRobotics (PRCT) to $30 from $47 but keeps a Buy rating on the shares. The company’s Q4 missed estimates, though its Analyst Day laid out a case for ...

Analysts expect PROCEPT BioRobotics to report an earnings per share (EPS) of $-0.32. PROCEPT BioRobotics bulls will hope to ...

Company outlines path to leadership in BPH, including near-term focus on procedure growth through patient-centric solutions and increased ...

SAN JOSE, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing ...

PROCEPT BioRobotics (NASDAQ:PRCT) reported fourth-quarter 2025 results that were marked by strong U.S. procedure growth but ...

The latest price target for PROCEPT BioRobotics (NASDAQ:PRCT) was reported by Truist Securities on December 18, 2025. The analyst firm set a price target for $47.00 expecting PRCT to rise to within 12 ...

Ratings for PROCEPT BioRobotics (NASDAQ:PRCT) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below provides a snapshot of their ...

Total revenue of $75.0 million for full year 2022, an increase of 118% compared to 2021 Total revenue of $23.8 million for the fourth quarter of 2022, an increase of 135% compared to the prior year ...

A live webcast of each event, as well as an archived recording, will be available on the "Investors” section of the Company’s website at: https://ir.procept-biorobotics.com. The webcasts will be ...

Procept is a medical technology company offering a surgical procedure for benign prostatic hyperplasia (“BPH”), the enlargement of the prostate as a man ages, which can disrupt or block the urethra ...